⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24777703 | 1.00 | — | — | |
| SCHEMBL19455913 | 1.00 | — | — | |
| SCHEMBL16409904 | 1.00 | — | — | |
| SCHEMBL26178358 | 1.00 | — | — | |
| SCHEMBL23253011 | 1.00 | — | — | |
| Hydroxyamine SCHEMBL10965157 | 0.97 | TSHR (0.38) | — | |
| SCHEMBL14535045 | 0.82 | CA1 (0.35) | — | |
| SCHEMBL16225030 | 0.82 | CA1 (0.35) | — | |
| SCHEMBL23718455 | 0.80 | CA1 (0.34) | — | |
| SCHEMBL28319829 | 0.79 | METAP1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235258-B1 | Sustained-release formulations for treating CNS-mediated disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | claimed |
| EP-1576962-A1 | Composition comprising isovaleramide and ibuprofen | NPS PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040072900-A1 | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound | NPS PHARMACEUTICALS | 2004-04-15 | — | — | US | claimed |
| JP-2002538106-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1225888-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2002-07-31 | — | — | EP | claimed |
| US-6383527-B1 | FOR TREATMENT OF ACUTE MUSCULAR ACHES, STRAINS, AND SPRAINS WHICH OCCUR FROM A LOCALIZED, EXTERNAL INSULT TO A PARTICULAR MUSCLE OR MUSCLE GROUP | NPS PHARMACEUTICALS, INC. | 2002-05-07 | — | — | US | claimed |
| EP-1176953-A2 | TREATMENT OF A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2001028516-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2000051586-A2 | TREATING A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0143001-B1 | PYRIMIDOISOQUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
| US-4673676-A | Pyrimidoisoquinoline derivatives useful for treating allergies | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-16 | — | — | US | claimed |
| EP-0143001-A2 | Pyrimidoisoquinoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-29 | — | — | EP | claimed |
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-31 | — | — | US | disclosed |
| EP-4071239-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-114901810-A | Method for culturing hematopoietic stem cells | 住友制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| EP-0414058-A2 | Carboxylic acid derivatives | BASF Aktiengesellschaft (DE) | 1991-02-27 | — | — | EP | disclosed |
| US-4673676-A | Pyrimidoisoquinoline derivatives useful for treating allergies | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-16 | — | — | US | disclosed |
| US-4618610-A | Triazine derivatives, and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-21 | — | — | US | disclosed |
| EP-0123254-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |